Cephalon, Schering-Plough deal

The companies renewed for up to five years their agreement to develop compounds for Alzheimer's disease. Under the new agreement, CEPH will receive $32 million in research and milestone payments, an option to co-promote in the U.S. products that are developed in the agreement, and royalties on sales outside of the U.S. ...